Cenova Capital

Cenova Capital is a venture capital firm based in Shanghai, China, founded in 2010 by Dr. Jun Wu. The firm specializes in late venture and growth stage investments in the life sciences and healthcare sectors. Cenova focuses on various sub-sectors, including pharmaceuticals, medical technology, specialized healthcare services, precision medicine, e-health, and innovative medical devices and diagnostics. As one of the earliest dedicated healthcare investment firms in China, Cenova has played a significant role in transitioning the country's healthcare system from a state-owned model to a more market-oriented approach. The firm manages five funds and has invested in over 50 companies, with its investors primarily comprising large domestic and international institutional entities, such as sovereign wealth funds, government institutions, and multinational companies.

Frank Feng

CFO

Stella Kwek

Managing Director

Walter Lau

Co-Founder and Managing Partner

XIAOYIN SHEN M.A.

Managing Director

Adam Wang

Venture Partner

Jun Wu

Founder and Chairman

Melissa Zhang

Partner

Carroll Zhang

Managing Director

Kai Zhao

Managing Partner

30 past transactions

Yuanyin Bio

Series A in 2022
Yuanyin Bio is a biotechnology company focuses on the research and application of circular RNA technology in the field of innovative drugs and therapies, builds a robust pipeline of preventive and therapeutic new drugs, and is dedicated to addressing clinically unmet disease needs. They serve in the field of innovative drugs and therapies. It establishes a pipeline of preventive and therapeutic new drugs and is committed to solving clinically unmet disease needs.
Simple psychology belongs to Beijing Zhujian Technology Co., Ltd. Simple psychology focuses on providing high-quality psychological services.

TreeENT

Series A in 2022
TreeENT Health, established in 2017 and based in Hangzhou, China, operates as a specialized surgical center focusing on ear, nose, and throat (ENT) conditions. The company, also known as Renshu Medical, provides a comprehensive range of services for various ENT diseases, including suppurative otitis media, allergic rhinitis, chronic sinusitis, and thyroid cancer. Utilizing advanced technology, TreeENT offers minimally invasive surgical procedures, as well as diagnostic services such as Danish ear hearing detection, nasal endoscopy, and nasopharyngoscopy. Additionally, the company facilitates patient access through WeChat for appointment scheduling with medical experts. With a commitment to high-quality care, TreeENT aims to deliver professional medical services that align with international standards and support personalized chronic disease rehabilitation.

AnHeart Therapeutics

Series B in 2021
AnHeart Therapeutics is a clinical-stage biopharmaceutical company based in Hangzhou, China, founded in 2018. The company focuses on the discovery and development of innovative pharmaceutical products aimed at improving human health and the quality of life for cancer patients. AnHeart is dedicated to acquiring and commercializing novel therapies, with its lead product being AB-106, an oral small molecule inhibitor that selectively targets ROS1 and NTRK. Through its research and development efforts, AnHeart Therapeutics seeks to advance precision therapies that address the needs of individuals affected by cancer.

Yuanyin Bio

Seed Round in 2021
Yuanyin Bio is a biotechnology company focuses on the research and application of circular RNA technology in the field of innovative drugs and therapies, builds a robust pipeline of preventive and therapeutic new drugs, and is dedicated to addressing clinically unmet disease needs. They serve in the field of innovative drugs and therapies. It establishes a pipeline of preventive and therapeutic new drugs and is committed to solving clinically unmet disease needs.

Umai Technology

Series A in 2021
Umai Technology is a skin image management software firm providing image processing, information acquisition, and clinical diagnosis.

Forerunner Medical

Series B in 2021
Forerunner Medical (Shanghai) Co., Ltd. develops and manufactures medical devices for minimally invasive treatment. It primarily develops and produces low-temperature plasma radiofrequency generators and electrodes for sport medicine, disk demo-pression, and ENT treatment applications. Its products include plasma radiofrequency systems; and electrodes for joint, spine, cervical, lumbar, transforaminal endoscopic operation, and ENT treatment applications. The company was founded in 2009 and is based in Shanghai, China.

Bang Er Orthopedic

Series D in 2021
Zhejiang Boner Medical Investment Management Co., Ltd. is a well-known professional hospital investment operator in the Yangtze River Delta, featuring major orthopaedics and rehabilitation.

Weimai

Series C in 2020
Weimai is a developer of a health application platform intended to provide medical and health services. The company's health application platform offers an Internet-based appointment, distribution, maternal and child disease management, grading diagnosis and treatment as well as remote diagnosis, and medical records management, providing users with a family doctor application in every home.

Unionlab

Series A in 2020
Unionlab provides clinical CRO services with a focus on the field of oncology. Unionlab delivers an integrated service from the strategy to implementation, including strategy consultation, medical affairs, clinical study operation, third-party independent imaging review, data management, bioanalysis, FSP, and other related services.

Baikemy.com

Series B in 2019
Baikemy.com is a health encyclopedia based in Beijing, China, focused on delivering authoritative healthcare knowledge to users. The platform serves as a scientific and practical resource for the dissemination and exchange of medical information, offering a range of products including authoritative articles and medical videos. Baikemy.com collaborates with top-tier hospitals to create high-quality knowledge materials, enhancing users' understanding of health care. Its offerings include scientific articles, a mutual aid community, and comprehensive medical information services, all designed to empower individuals with reliable health-related knowledge.

Weimai

Series C in 2019
Weimai is a developer of a health application platform intended to provide medical and health services. The company's health application platform offers an Internet-based appointment, distribution, maternal and child disease management, grading diagnosis and treatment as well as remote diagnosis, and medical records management, providing users with a family doctor application in every home.

Phoebus

Series A in 2018
Phoebus Medical Technology is a Healthcare company.

Weimai

Series B in 2018
Weimai is a developer of a health application platform intended to provide medical and health services. The company's health application platform offers an Internet-based appointment, distribution, maternal and child disease management, grading diagnosis and treatment as well as remote diagnosis, and medical records management, providing users with a family doctor application in every home.

Luqa Pharmaceuticals

Series B in 2018
Luqa Pharmaceuticals Co., Ltd. is a specialty pharmaceutical company focused on the Chinese market, primarily engaged in the acquisition, development, and commercialization of healthcare products. The company offers a diverse portfolio that includes dermatological and oral care products. Its dermatological offerings feature Ebernet, an eberconazole cream for fungal skin infections, and Strataderm, a silicone gel for scar treatment and prevention. In the oral care segment, Luqa provides Lacteol, a probiotic for infants and immunocompromised patients, and GelX, a medical device for managing oral cavity pain from conditions like mucositis and stomatitis. Other products include GelX Xero for dry mouth relief, Aftacure for oral mucosal lesions, Ialuxid Gel for post-surgical wounds, and Podofilm for benign epithelial formations. Established in 2010 and based in Central, Hong Kong, Luqa Pharmaceuticals is dedicated to enhancing patient quality of life through innovative healthcare solutions.

Virtus Medical Holding

Venture Round in 2018
Virtus Medical Holding is a provider of outpatient medical services that integrates a diverse range of healthcare disciplines to offer comprehensive care. The organization focuses on patient-centered care coordination, facilitating services from wellness and prevention to treatment and rehabilitation for individuals at various stages of the health cycle. Virtus combines high-end specialists with state-of-the-art healthcare facilities to deliver essential medical procedures, including physiotherapy, surgery, vaccinations, and rehabilitation services. Its commitment to integrated healthcare is exemplified through the establishment of an integrated medical tower and a custom clinic management system, supported by a team of health consultants dedicated to optimizing patient care.

Vivace Therapeutics

Series B in 2017
Vivace Therapeutics, Inc. is a small molecule discovery and development company focused on creating innovative cancer therapeutics by targeting the Hippo pathway, which plays a critical role in tissue regeneration and organ development. Founded in 2014, the company is based in San Mateo, California, and operates with a commitment to advancing novel therapies that can improve outcomes for cancer patients. Vivace Therapeutics emphasizes a capital-efficient and modality-indifferent approach, collaborating with leading academic laboratories to leverage cutting-edge research. Its experienced management team and top-tier scientists aim to develop treatments that can be used independently or in combination with existing therapies, ultimately striving to enhance the lives of individuals affected by cancer.

LinkDoc

Series B in 2016
LinkDoc Technology Limited develops medical data solutions and oncology big data platforms. It offers clinical structured data for oncology hospitals and hospitals to assist hospitals in solving scientific and clinical problems. The company was founded in 2014 and is headquartered in Beijing, China.

AoHua

Series C in 2016
Aohua Endoscopy Co., Ltd. is a manufacturer of endoscopy equipment and consumables, offering a range of products including imaging processors, endoscopes, and various accessories. The company specializes in solutions for gastroenterology, respiratory care, ear, nose, and throat (E.N.T) applications, as well as veterinary endoscopy. Founded in 1994, Aohua is headquartered in Shanghai, China, and aims to lead in the innovation of endoscope technology while advancing the field of endoscopic diagnosis and treatment.

ASLAN Pharmaceuticals

Series C in 2015
ASLAN Pharmaceuticals is a clinical-stage biopharmaceutical company based in Singapore, specializing in immunology and oncology. Founded in 2010, the company focuses on developing innovative treatments aimed at improving patient outcomes. Its clinical portfolio includes ASLAN004, a monoclonal antibody therapy for atopic dermatitis and other immunological conditions, as well as small molecule inhibitors targeting various cancer types. ASLAN collaborates with notable partners such as Almirall, Array BioPharma, Bristol-Myers Squibb, and CSL Limited to enhance its research and development efforts. The company is dedicated to creating novel medicines for both Asian and global markets.

Yaoshi Quanyun Jiankang

Angel Round in 2015
Shanghai Yaoshi Quanyun Health Technology Development Co., Ltd. develops health, science, and technology software. The company was founded in 2015 and is based in Shanghai, China.

INNOMED

Series A in 2015
Suzhou Innomed Medical Device Co., LTD, doing business as Inno-Hydrowire, designs, manufactures, and distributes implantable medical device products for interventional procedures. Its product consists nickel-titanium alloy core wire; a polymer coating (pebax containing BaSO4 for X-Ray visibility); and a hydrophilic coating applied to the entire wire; and it is intended to direct a catheter to an anatomical location in the vasculatory system during diagnostic or interventional procedures. The company was founded in 2013 and is based in Suzhou, China.

Juliye

Series A in 2015
Operator of the online-to-off-line platform created to connect medical needs and healthcare resources.

Etong Healthcare

Series A in 2015
EtongOnline Shanghai Medical Consulting provides third-party health management services to large and medium-sized enterprises in Shanghai, Beijing, Shenzhen, Guangzhou, Wuhan, & Chengdu. Its healthy management services include file recording, health assessment, health intervention, health education, health consultation, and private doctor services. The company also provides health examination services, such as employment health check, physical examination, PET-CT testing, gene detection, and enterprise welfare health check services. In addition, it offers medical services, such as medical guidance, specialist appointment, admission solutions, surgery appointment, secondary consultation, and particular examination arrangement services. Further, the company provides services in the areas of establishment of health infirmary, enterprise stratified health management, overseas medical, medical tourism, liability insurance, and oral care. EtongOnline Shanghai Medical Consulting was founded in 2009 and is headquartered in Shanghai City, China.

Etong Health

Series A in 2015
Provider of an online health management service platform intended to offer third-party health management services to large and medium-sized enterprises. The company's platform include services like file recording, health assessment, health intervention and health related education and consultation services, enabling its clients to receive an array of one-stop health check services.

IMPACT Therapeutics

Series A in 2014
IMPACT Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and commercializing therapeutics for cancer and other serious diseases. Founded in 2009 and headquartered in Shanghai, China, the company is engaged in several research and development projects, including the development of PARP inhibitors, Wee1 inhibitors, novel DNA damage response agents, and Hedgehog pathway inhibitors. IMPACT Therapeutics aims to create best-in-class drugs with independent intellectual property rights, emphasizing the discovery of targeted anti-cancer therapies based on the principle of synthetic lethality. The company’s management team possesses extensive experience in drug development and management, with a strong background in pharmacology and biology, which supports its mission to provide innovative treatments for patients with life-threatening conditions.

ASLAN Pharmaceuticals

Series B in 2013
ASLAN Pharmaceuticals is a clinical-stage biopharmaceutical company based in Singapore, specializing in immunology and oncology. Founded in 2010, the company focuses on developing innovative treatments aimed at improving patient outcomes. Its clinical portfolio includes ASLAN004, a monoclonal antibody therapy for atopic dermatitis and other immunological conditions, as well as small molecule inhibitors targeting various cancer types. ASLAN collaborates with notable partners such as Almirall, Array BioPharma, Bristol-Myers Squibb, and CSL Limited to enhance its research and development efforts. The company is dedicated to creating novel medicines for both Asian and global markets.

fUGAO

Series B in 2013
Provider of integrated services for medical information systems. The company's integrated services utilize high-tech enterprises, dual-soft certification, system integration (three) qualification, CMMI3 , ISO9001 and other qualifications, providing hospital information platform, clinical data center, clinical management system, telemedicine, mobile medical, medical BI system, neonatal screening and other emerging products.

AoHua

Series A in 2013
Aohua Endoscopy Co., Ltd. is a manufacturer of endoscopy equipment and consumables, offering a range of products including imaging processors, endoscopes, and various accessories. The company specializes in solutions for gastroenterology, respiratory care, ear, nose, and throat (E.N.T) applications, as well as veterinary endoscopy. Founded in 1994, Aohua is headquartered in Shanghai, China, and aims to lead in the innovation of endoscope technology while advancing the field of endoscopic diagnosis and treatment.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.